Full-text resources of PSJD and other databases are now available in the new Library of Science.
Visit https://bibliotekanauki.pl
Preferences help
Polish version English version Language
enabled [disable] Abstract
Number of results

Results found: 2

Number of results on page
first rewind previous Page / 1 next fast forward last

Search results

help Sort By:

help Limit search:
first rewind previous Page / 1 next fast forward last
1
Publication available in full text mode
Content available

Long-term disease control during TAS-102 therapy in the VI line treatment in a 73-year-old mCRC patient. A case report

100%
Skalij P., Tokajuk P., Jelski S., Wojtukiewicz M.
OncoReview
|
2020
|
vol. 10
|
issue 1
15-17
EN
A case of 73-year-old patient with metastatic colorectal cancer who underwent trifluridine/tipiracil therapy within the VI line was presented. Treatment with trifluridine/tipiracil allowed to achieve stabilization of the existing cancer for nearly 7 months.
2
Content available remote

TAS-102 – a new option in the treatment of patients with advanced colorectal cancer after failure or intolerance to other therapies

100%
Skalij P., Tokajuk P., Wojtukiewicz M. Z.
OncoReview
|
2020
|
vol. 10
|
issue 1
8-14
EN
Colorectal cancer is the second cause of death from malignant cancer, following lung cancer. Approximately 35–45% of patients with colorectal cancer will develop distant metastases over time. Palliative systemic treatment remains the standard for non-operative distant metastases. TAS-102 is a novel orally administered antineoplasmatic thymidine-based nucleoside analog which represents an approved option for the treatment of advanced metastatic colorectal cancer in patients who are refractory, or are not considered canditates for, currently available therapies.
first rewind previous Page / 1 next fast forward last
JavaScript is turned off in your web browser. Turn it on to take full advantage of this site, then refresh the page.